• Galapagos entered binding framework agreement with Gilead to collaborate on Ouro Medicines’ T cell engager programs for autoimmune diseases, led by clinical-stage gamgertamig (OM336).
• Deal becomes effective on completion of Gilead’s acquisition of Ouro, valued at USD 1.7 billion upfront with up to USD 500 million in milestones.
• Galapagos will fund 50% of acquisition consideration, including 50% of any contingent milestones.
• Licensing terms give Galapagos development rights to gamgertamig, with pre-registrational development costs borne by Galapagos.
• Gilead will lead commercialization outside KeyMed territories, paying Galapagos tiered royalties of 20%-23% on net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galapagos NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603310130PRIMZONEFULLFEED1001173217) on March 31, 2026, and is solely responsible for the information contained therein.